Nivolumab and Ipilimumab: Efficacy of Immunotherapy for Kidney Cancer
In April 2018, the United States Food and Drug Administration (FDA) approved the combination of immunotherapy drugs ipilimumab (Yervoy) and nivolumab (Opdivo) as a form of first-line or initial treatment for people diagnosed with advanced kidney cancer — whose malignant disorder has an intermediate or poor prognosis, according to the National Cancer Institute.
A promising sign of progression in the field of cancer eradication, initial treatment using these medications is the first immunotherapy regimen that the FDA approved for patients with kidney cancer. Nivolumab alone was previously approved to help patients with advanced kidney cancer, particularly
: Use of undefined constant rand - assumed 'rand' (this will throw an Error in a future version of PHP) in /homepages/4/d181863590/htdocs/12/wp-content/themes/ribbon/single.php
on line 48